Antiepileptic Drugs Market Overview
Antiepileptic Drugs Market size is estimated to reach $21.4 billion by 2027, growing at a CAGR of 2.6% during the forecast period 2022-2027. Antiepileptic drugs are also delineated as anticonvulsants that are taken into account to treat seizure disorders which are commonly known as “Epilepsy.” This condition can set many complications like muscle stiffness, atypical sensations, abnormal behavior, and others in motion. At worst patient may slide into oblivion. There is no one particular cause of epilepsy. It can be stimulated by genetic influence, brain injuries, infections prenatal injury, and many more. There are several anticonvulsants or antiepileptic drugs such as valproic acid, and eslicarbazepine acetate (= aptiom, zebnix) which are leading medicines in the treatment of epilepsy. The effect of uridine glucuronosyltransferase (UGT)1A6 genetic polymorphism on valproic acid pharmacokinetics is widely acknowledged. Furthermore, Therapeutic drug monitoring assists in epilepsy treatments by measuring the medicine amount present in the blood. The antiepileptic drugs market outlook is exceptionally enchanting with shooting up demand. Augmenting consumption of alcohol, stress, and depression bound with desires for a successful life, and proliferating incidences of serious injuries while impaired with alcohol and drugs are factors set to drive the growth of the Antiepileptic Drugs Industry for the period 2022-2027.
The report: “Antiepileptic Drugs Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Antiepileptic Drugs Market
- Geographically, the North America Antiepileptic Drugs Market accounted for the highest revenue share in 2021. It is owing to the presence of robust infrastructural capabilities which enhances the diagnosis to cure ratio, supplementing the market growth. Nevertheless, Asia-Pacific is poised to dominate the market over the period 2022-2027.
- The far-reaching prevalence of epilepsy seizures is said to be the preeminent driver driving the growth of the Antiepileptic Drugs Market. Besides, several side-effects connected with anticonvulsants are said to reduce the market growth.
- A detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Antiepileptic Drugs Market report.
Antiepileptic Drugs Market- Geography (%) for 2021
For more details on this report - Request for Sample
Antiepileptic Drugs Market Segment Analysis-By Drug Type
The Antiepileptic Drugs Market based on the drug type can be further segmented into the first generation (Mysoline, Zarontin, Carbatrol, Topamax, luminal, and others), second-generation (=Vimpat, Lyrica, Keppra, Aptiom, Banzel, Fycompa, and others), and third-generation drugs. The second-generation segment held the largest share in 2021. The growth is owing to higher effectiveness as compared to other categories of drugs. These drugs work by either controlling the impulse or enhancing the inhibition. Moreover, they are capable of affecting the pore-forming membrane proteins commonly termed ion channels and varying the neurons' electrical activity. However, the third-generation drugs segment is estimated to be the fastest-growing with a CAGR of 3.4% over the forecast period 2022-2027. This growth is owing to augmenting focus of companies on the production of third-generation drugs. Considering the before long expiration of patents on second-generation drugs companies are stepping up their efforts and allocating the innumerable amount of funds to research and development activities.
Antiepileptic Drugs Market Segment Analysis-By Distribution Channel
The Antiepileptic Drugs Market based on distribution channels can be further segmented into offline channels (=hospital pharmacies, retail pharmacies, drug stores, and others), and online platforms. The offline segment held the largest share in 2021. The growth is owing to the full-fledge and all-encompassing nature of offline facilities as compared to online. Offline platforms like hospitals and retail pharmacies have their presence in pastoral areas also which makes them the first point of contact for more than 40% of the population because 45-46% of the world population still reside in the countryside as of 2021. Moreover, the availability of top-flight doctors and the well-equipped nature of hospitals encourage people to undergo treatments which can be a driving factor in the growth of the respective market. Nevertheless, the offline segment is estimated to be the fastest-growing with a CAGR of 3.8% over the forecast period 2022-2027. This growth is owing to the unbelievable pace at which digitalization is spreading across rural areas. With 24/7 access to networks, people are becoming more technology-friendly. Consequently, they are choosing online pharmacies over offline as buying online is much more convenient and saves time also.
Antiepileptic Drugs Market Segment Analysis-By Geography
The Antiepileptic Drugs Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 36% of the overall market in 2021. The growth in this segment is owing to the factors such as to-notch quality of healthcare infrastructure which is promoting better treatment and diagnosis rates. The U.S. and Canada have a network of world-class hospitals and research labs which gives this segment a strategic edge over the rest of the world in extending better patient care and novel drug discovery. On another hand, owing to high living standards people due to affluent economies people living in these countries are considered to be more health-conscious and financially capable to undergo curing treatments. However, Asia-Pacific is estimated to offer lucrative growth opportunities over the forecast period 2022-2027. This growth is owing to an escalation in the prevalence of neurological disorders. Many people in Asian nations like India, Bangladesh, Pakistan, Nepal, and others still live in impoverished areas with no adequate infrastructure. Therefore, to delude the reality and forget their day-to-day problems they tend to associate with alcohol and marijuana which brings them one step closer to mental concussion and epileptic disorders. Additionally, other nations like Japan, China, Australia, and New Zealand have their fair share in the growth of their respective market because prospering economies of these countries allows them to spend billions of dollars on research.
Antiepileptic Drugs Market Drivers
Broadening cases of stress, depression, and accidents are Anticipated to Boost Product Demand.
We all are living in a dynamic era where one has to put constant efforts in order to keep up with ever-growing competition otherwise, they may lag. In their pursuit of achieving something big or living a successful life people are constantly driving them into depression. This constant unrest is one of the biggest reasons behind mental disorders. According to a WHO study, around 3.8-4% of the world population is afflicted with depression. Most depressed people slide themselves into serious epileptic complications. On another hand, severe injuries connected with accidents are another major factor driving the growth in the antiepileptic drugs market. a study by the Center for Disease Control (CDC) claimed that more than 28-29% of brain injuries are linked to road accidents. Consequently, heightening road tragedies can be a factor of growth in the respective market.
A massive push of companies in the development of novel third-generation drugs is Expected to Boost Product Demand.
It should not come as a surprise that epileptic seizures are more common in the elderly population. Therefore, as the old-age population of the world is anticipated to touch the 1-2 billion mark within a few years various companies in their respective fields have stepped up their efforts to meet the rising demand and make profits. Market players are allocating innumerable flows of hard cash into research and development processes to fabricate a more effective and stable alternative to 2nd generation drugs. Besides, patent expiration several second-generation medications are imminent which is another potential driver for the growth of the antiepileptic drugs market. Furthermore, an active push has been made in treating the associated ailments which come along with epilepsy. For example, LGS ( Lennox-Gastaut Syndrome), a severe childhood-onset developmental and epileptic encephalopathy characterized by drug-resistant seizures with high morbidity as well as a serious impairment of neurodevelopmental, cognitive, and motor functions affects nearly 30-50,000 patients in the U.S.
Antiepileptic Drugs Market Challenges
Several health hitches accompanied by these drugs are Anticipated to Hamper Market Growth.
In a few parts of the world talking about such neurological abnormalities is still considered taboo. Therefore, rather than revealing and undergoing a treatment people try to hide such complications which can strangle the growth in the respective market. Moreover, there are several health hitches of antiepileptic drugs that refrain people from consuming them. These medications can set hepatoxicity, nephrolithiasis, obesity, mental slowdown, skin problems, and many more in motion which is anticipated to cripple the growth of the antiepileptic drugs market. Furthermore, epilepsy-resistant drugs are a huge concern for various public health authorities as the numbers for the same are growing at a rampant pace. As in the globe, around 1 million people have shown resistance to such drugs which would force newer lines of medications to develop.
Antiepileptic Drugs Industry Outlook:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antiepileptic Drugs Market. Key companies of this market are-
- Abbott Laboratories
- Johnson & Johnson
- Sanofi S.A.
- Valeant Pharmaceuticals International
- UCB Pharma
- Pfizer Inc.
- Novartis International AG.
- Sunovion Pharmaceuticals
- Cephalon Inc.
- In April 2022, Neuro-Pace announced the first patient being treated in a Pivotal Study evaluating the RNS Systems in adolescents aged between 12 through 17. Additionally, the following technology comes as an alternative to the already available anti-epileptic drugs. As per various research published by the company around 1 million people live through drug-resistant epilepsy. The RNS System has demonstrated unprecedented seizure reduction and improved quality of life in adults with drug-resistant focal epilepsy.
- In May 2022, JAMA Neurology published Phase-3 study results on the efficacy and safety of FINTEPLA Oral Solution for LGS ( Lennox-Gastaut Syndrome ). Multi-center, double-blind, placebo-controlled, parallel-group, randomized Phase 3 trial demonstrating that FINTEPLA 0.7 mg/kg/day, when added to a patient's current anti-epileptic treatment regimen for seizures associated with LGS, is effective in reducing the frequency of drop seizures.
- On November 12, 2020, Brussels, Belgium-based biopharmaceutical company “Union Chimique Belge”, commonly known as UCB announced the acquisition of “Handl Therapeutics.” Handl is headquartered in Leuven, Belgium, and is famous for its gene therapies which help in the treatment of neurodegenerative illnesses.
Brain Tumor Treatment Market – Forecast (2022 - 2027)
Report Code: HCR 0257
Rare Neurological Disease Treatment Market-Forecast (2022 – 2027)
Report Code: HCR 42071